department by their handler, and per protocol, did not visit the critically ill and suicidal patients. Upon arrival, all tests at baseline were negative for all 7 dogs. Following the dogs' visits through the emergency department, all tests were negative for the 7 dogs on post-measure. Microbial analysis of the collected samples revealed that all 7 dogs carried commensal skin flora, even after very close contact with the patients who involved petting, hugging, and kissing the dogs. There was no growth of the pathogens of concern, namely E. coli, MRSA, C. diff, and Pseudomonas.
Study Objectives: Value-based purchasing (VBP) is a quality incentive program under the Affordable Care Act that is funded by a 2% reduction from diagnosis-related group (DRG) payments for the 2018 fiscal year. One-quarter of this fund is determined by patient and caregiver-centered experience and care coordination. Therefore, patient satisfaction scores have become an increasingly important component of health care delivery. Few studies have sought to identify low-cost interventions that improve patient experience and subsequently patient satisfaction scores. Here, we aim to explore the impact of popsicle administration in pediatric emergency department (ED) patients on Press Ganey satisfaction scores.
Methods: A prospective trial was conducted at a tertiary academic pediatric ED and one mid-sized community ED between January 2018 to March 2018. The intervention was to give a popsicle to all eligible patients 0-14 years of age on even-numbered days (popsicle days) versus conventional practice on odd-numbered days. Press Ganey top box scores (response to the question was a "5" or the highest value) between even-and oddnumbered days were then compared using 2-sample t and chi-square tests.
Results: Among the 152 pediatric patients included (0-14 years of age), 84 surveys were filled out on even days and 68 surveys were filled out on odd days. Baseline demographics were similar between the groups with an average age of 7.3 AE 6.0 years and no statistical difference between the number of male and female patients. Overall, there was a significant increase in patient satisfaction scores on popsicle administration days for questions that asked about physician's concern for comfort 74% versus 58% (p < 0.05), physician's courtesy 77% versus 62% (p < 0.04), and physician taking time to listen 74% versus 57% (p < 0.03). No statistical difference was observed for questions that asked about overall rating of care 64% versus 61% (p¼ 0.64), likelihood of recommending 66 versus 59% (p¼0.37), or informed of treatment 74% versus 60% (p¼0.07).
Conclusions: Offering popsicles to all eligible pediatric emergency department patients resulted in an increase in Press Ganey patient satisfaction score regarding physician's concern for comfort, courtesy, and listening. Further studies should increase sample size, assess subsets of age groups, and assess economic rate of return for this and other low-cost interventions that might significantly impact perceived health care quality.
Feasibility of Delivering Patiromer Through Enteral Feeding Tubes
Gross C, Bartis J, Nwachukwu F, Ono R, Li L/Relypsa, Inc, a Vifor Pharma Group Company, Redwood City, CA Study Objectives: Patiromer is a sodium-free potassium binder approved for the treatment of hyperkalemia (HK) in the U.S. and E.U. The efficacy and safety of patiromer in pediatric patients are currently under investigation (EMERALD, NCT03087058). Patiromer in doses of 8.4, 16.8, and 25.2 g is supplied as a powder, and based on the label should be reconstituted in 1/3 c. water (w80 mL) to obtain a suspension for oral administration. This presents a clinical challenge because pediatric patients with chronic kidney disease and HK may use enteral feeding tubes for nutritional needs and medication administration. The objective of this series of experiments was to evaluate the feasibility of patiromer delivery through enteral feeding tubes.
Methods: Patiromer suspensions delivered via syringe (12, 35, and 60 mL) through nasogastric (NG; 5, 6.5, 8, and 14 Fr) and gastrostomy tubes (GT; 12 and 14 Fr) were evaluated under gravity flow. Dose recovery and flow rate were determined based on tube diameter and suspension concentration (4.2, 8.4, 16.8, and 25.2 g in 80 and/or 90 mL water). Clumping and adherence of drug product to the tubing wall were also evaluated. Force applied to the syringe to facilitate delivery of patiromer to the tubes was assessed using the 8.4 g dose suspended in 90 mL water.
Results: Patiromer 8.4 g/90 mL water was aspirated and delivered by syringe with no evidence of clogging or blockage. Dose recovery of patiromer suspensions of 4.2 to 16.8 g in 80 and/or 90 mL water through 5, 6.5 and 8 Fr NG and 12 Fr GT was 93-101%. Flow rate increased with decreasing suspension concentration ( Figure) . Flow rate also increased with increasing tube diameter. Patiromer 4.2 to 16.8 g/80 mL suspensions flowed through all tubes tested except the 5 Fr NG tube, while patiromer 25.2 g/80 mL did not flow through any of the tubes tested. Significant adherence to the tube walls did not occur in tubes tested with 8.4 g suspensions. Application of gentle pressure to the syringe facilitated flow especially through smaller tubes.
Conclusions: Results showed that the delivery of patiromer at concentrations up to 8.4 g/80 mL through NG and GT of 6.5 Fr to 14 Fr is feasible, with delivery improving upon use of larger diameter tubes. Patiromer 16.8 g/80 mL is deliverable through tubes >8 Fr. It is possible that additional dilution or applied pressure will achieve flow through smaller feeding tubes or with patiromer doses >16.8 g; however, consideration should be made for hyperkalemic patients under fluid restriction.
